» Articles » PMID: 31484562

HIV-2 As a Model to Identify a Functional HIV Cure

Abstract

Two HIV virus types exist: HIV-1 is pandemic and aggressive, whereas HIV-2 is confined mainly to West Africa and less pathogenic. Despite the fact that it has been almost 40 years since the discovery of AIDS, there is still no cure or vaccine against HIV. Consequently, the concepts of functional vaccines and cures that aim to limit HIV disease progression and spread by persistent control of viral replication without life-long treatment have been suggested as more feasible options to control the HIV pandemic. To identify virus-host mechanisms that could be targeted for functional cure development, researchers have focused on a small fraction of HIV-1 infected individuals that control their infection spontaneously, so-called elite controllers. However, these efforts have not been able to unravel the key mechanisms of the infection control. This is partly due to lack in statistical power since only 0.15% of HIV-1 infected individuals are natural elite controllers. The proportion of long-term viral control is larger in HIV-2 infection compared with HIV-1 infection. We therefore present the idea of using HIV-2 as a model for finding a functional cure against HIV. Understanding the key differences between HIV-1 and HIV-2 infections, and the cross-reactive effects in HIV-1/HIV-2 dual-infection could provide novel insights in developing functional HIV cures and vaccines.

Citing Articles

The role of heat shock proteins in HIV-1 pathogenesis: a systematic review investigating HSPs-HIV-1 correlations and interactions.

Nastiti C, Syakdiyah N, Hawari R, Ophinni Y, Megasari N PeerJ. 2024; 12:e18002.

PMID: 39308823 PMC: 11416755. DOI: 10.7717/peerj.18002.


The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.

Thavarajah J, Honge B, Wejse C Viruses. 2024; 16(6).

PMID: 38932203 PMC: 11209272. DOI: 10.3390/v16060911.


The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.


New Insights into HIV Life Cycle, Th1/Th2 Shift during HIV Infection and Preferential Virus Infection of Th2 Cells: Implications of Early HIV Treatment Initiation and Care.

Hokello J, Tyagi K, Owor R, Sharma A, Bhushan A, Daniel R Life (Basel). 2024; 14(1).

PMID: 38255719 PMC: 10817636. DOI: 10.3390/life14010104.


The HIV-2 OGH double reporter virus shows that HIV-2 is less cytotoxic and less sensitive to reactivation from latency than HIV-1 in cell culture.

Bruggemans A, Vansant G, Van De Velde P, Debyser Z J Virus Erad. 2023; 9(3):100343.

PMID: 37701289 PMC: 10493508. DOI: 10.1016/j.jve.2023.100343.


References
1.
Wejse C, Honge B . Is it time to revise the notion that HIV-2 is benign?. Lancet HIV. 2018; . DOI: 10.1016/S2352-3018(18)30265-0. View

2.
Jaffar S, Wilkins A, NGom P, Sabally S, Corrah T, Bangali J . Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 16(5):327-32. DOI: 10.1097/00042560-199712150-00003. View

3.
Andersson S, Da Silva Z, Norrgren H, Dias F, Biberfeld G . Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS. 1997; 11(15):1815-22. DOI: 10.1097/00002030-199715000-00005. View

4.
Van Rompay K . The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses. 2011; 28(1):16-35. DOI: 10.1089/aid.2011.0234. View

5.
Jespersen S, Honge B, Krarup H, Medstrand P, Sorensen A, Medina C . Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2018; 79(3):386-393. DOI: 10.1097/QAI.0000000000001820. View